Latest Ratios: P/E Ratio -29.2x · EV/EBITDA N/A · ROE -0.0%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $6M | $287M | — | — | — | — |
| Enterprise Value | $-2896649581 | $-2615290385 | — | — | — | — |
| P/E Ratio → | -29.19 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.03 | 0.08 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -0.0% | -0.0% | -187.4% | -155.6% | -180.3% | -188.2% |
| ROA | -0.0% | -0.0% | -61.4% | -66.0% | -104.3% | -182.6% |
| ROIC | -0.0% | -0.0% | — | — | -3488.7% | — |
| ROCE | -0.0% | -0.0% | -166.5% | -121.7% | -101.0% | -187.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.08 | 0.19 | 0.14 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.83 | -1.49 | -1.82 | -1.23 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — |
Net cash position: cash ($2.9B) exceeds total debt ($1M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 2.09 | 2.09 | 1.12 | 0.85 | 1.67 | 32.22 |
| Quick Ratio | 2.09 | 2.09 | 1.12 | 0.85 | 1.67 | 32.22 |
| Cash Ratio | 1.01 | 1.01 | 0.95 | 0.80 | 1.60 | 2.33 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $21M | $22M | $125M | $125M | $22M |
Pre-revenue clinical execution risk
According to current market data, ADVB trades at a P/B ratio of 0.03, a valuation level that suggests investors are heavily discounting the company's reported assets, likely due to the persistent lack of commercial revenue and the inherent uncertainty surrounding its clinical-stage diagnostic pipeline.
The extremely low P/B ratio indicates that the market assigns almost no value to the company's book assets, potentially reflecting concerns regarding the liquidity of its cash reserves or the viability of its clinic-based business model. This valuation gap warrants further investigation into whether the market perceives the company's R&D efforts as value-destructive rather than value-accretive.
Based on reported financial figures, ADVB's ROIC has fluctuated significantly, reaching a low of -41.2% in 2026Q1, which underscores the company's inability to generate positive returns on invested capital while it continues to fund its pre-commercial microfluidic diagnostic development and clinic expansion.
The volatility in ROIC, coupled with persistent negative ROE, suggests that the company is currently destroying shareholder value through its high-burn operational strategy. Investors should monitor whether management can achieve a pivot toward positive returns as clinical trials for A+LCGuard progress, or if the current capital allocation remains inefficient.
As reported in recent quarterly filings, ADVB's current ratio reached 7.38 in 2026Q3, providing a substantial liquidity cushion that appears to insulate the firm from immediate insolvency despite the ongoing absence of revenue and the high costs associated with its diagnostic clinic operations.
While the high current ratio suggests a strong short-term position, the rapid contraction of total assets over the same period implies that this liquidity may be depleting faster than the company can establish a sustainable revenue stream. The reliance on cash reserves to maintain operations suggests that the company's liquidity position is highly sensitive to the pace of its clinical trial expenditures.
The P/E ratio is frequently misapplied to ADVB, as the company's pre-revenue status renders earnings-based multiples entirely meaningless and obscures the critical importance of cash burn rates and clinical milestone progress in evaluating the company's long-term viability as a diagnostic technology provider.
Investors should instead focus on cash burn and the installed base of diagnostic units, as these metrics provide a more accurate reflection of the company's operational progress than traditional valuation multiples. Relying on P/E or PEG ratios in this context may lead to a fundamental misunderstanding of the company's risk profile and its reliance on external capital.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ADVB stock.
Advanced Biomed Inc. Common Stock's current P/E ratio is -29.2x. This places it at the 50th percentile of its historical range.
Advanced Biomed Inc. Common Stock's return on equity (ROE) is -0.0%. The historical average is -142.3%.
Based on historical data, Advanced Biomed Inc. Common Stock is trading at a P/E of -29.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.